Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample f a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
April 14, 2020
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
June 12, 2015
Date of Patent:
March 31, 2020
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: The present invention provides kits, methods, and apparatus for analysing a biological sample from an animal to predict (pre-symptomatically) and monitor the development of sepsis, utilising biomarker signatures, and especially biomarker signatures capable of providing a mean predictive accuracy of at least 92% to differentiate development of sepsis from non-sepsis.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
March 24, 2020
Assignee:
The Secretary of State for Defence
Inventors:
Phillippa Maria Spencer, Roman Antoni Lukaszewski, Laura Craddock, Helen Eleri Jones
Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
June 12, 2015
Date of Patent:
March 24, 2020
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
Abstract: This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.
Type:
Grant
Filed:
June 16, 2015
Date of Patent:
March 24, 2020
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
March 17, 2020
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
Type:
Grant
Filed:
October 20, 2016
Date of Patent:
March 3, 2020
Assignees:
Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, The Technical University of Denmark
Inventors:
Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.
Type:
Grant
Filed:
August 24, 2012
Date of Patent:
January 7, 2020
Assignees:
Commonwealth Scientific and Industrial Research Organisation, Clinical Genomics Pty. Ltd.
Inventors:
Peter Laurence Molloy, Lawrence Charles Lapointe, Susanne Kartin Pedersen, Susan Margaret Mitchell
Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.
Abstract: A method for predicting the responsiveness of a cancer cell to an MEK inhibitor, comprising detecting the presence of at least one mutation in one or more genes selected from the group consisting of ADAM12, COL14A1, TNN, and TP53, in the cancer cell, by contacting a nucleic acid sample derived from the cancer cell with at least one oligonucleotide which allows specific detection of the mutation; wherein presence of mutation in ADAM12, COL14A1, TNN, TP53 and/or any combination thereof is indicative of decreased responsiveness of the cancer cell to the ERK inhibitor.
Abstract: The present invention relates to a method for identifying the variety of a hop by using an identification marker comprising at least one single nucleotide polymorphism that differs among varieties, and a method for preparing said identification marker. The present invention also provides a primer or a probe to be used in the method for identifying the variety of a hop, and a nucleic acid of a region including said identification marker. The present invention further provides a method for detecting the intrusion of different varieties in a hop sample.
Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
October 15, 2019
Assignee:
Becton, Dickinson and Company
Inventors:
James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
Abstract: Methods for selecting a medication for a patient are described that include determining the patient's genotype for a panel of genes, identifying a phenotype associated with the genotype for each gene, and selecting the medication based on the phenotype.
Type:
Grant
Filed:
October 20, 2011
Date of Patent:
October 8, 2019
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Abstract: A risk stratification method for a patient in a disease state and specifically patients presenting a tumor, includes determining if the patient is a homozygote or heterozygote and further determining the allelic expression for the patient, CC, T/C, or C/T. For patients having the cytosine methylated, they have a TIC allelic expression and patients without a methylated cytosine have a C/T allelic expression. A patient with a TT allelic expression is classified as a highest risk patient, a patient with a TIC allelic expression is classified as a second highest risk patient, a patient with a C/T allelic expression is classified as a third highest risk patients and a patient with a CC allelic expression is classified as a lowest risk patient. The risk stratification method may further include identification of an abnormal expression or mutation/function of a gene product produced by CTCF binding site 6.
Abstract: This disclosure generally relates to donor selection for hematopoietic stem cell transplantation. In particular, this disclosure relates to typing KIR3DL1 and HLA-B alleles as basis for donor selection.
Abstract: A method of evaluating a cancer cell sample, the method comprising: a. obtaining a cancer cell sample, optionally a breast cancer cell sample or an ovarian cancer cell sample, after the cancer cells have been exposed to a radiation dose; b. assaying the cancer cell sample to obtain a RNA integrity value and/or a RNA concentration of the cancer cell sample.
Type:
Grant
Filed:
December 3, 2013
Date of Patent:
August 20, 2019
Assignee:
RNA DIAGNOSTICS INC.
Inventors:
Mu Zhu, Amadeo Mark Parissenti, Laura Pritzker, Kenneth Pritzker, Stacey Santi, Baoqing Guo, Xiaohui Wang, Rashmi Narendrula
Abstract: A method of predicting an effect of an anti-c-Met antibody and/or selecting a subject for application of an anti-c-Met antibody including measuring a level of the biomarker in a biological sample, is provided.
Type:
Grant
Filed:
April 3, 2015
Date of Patent:
August 13, 2019
Assignee:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Jongsuk Chung, Tae Jin Ahn, Dae-Soon Son, Eunjin Lee
Abstract: Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture.
Type:
Grant
Filed:
October 24, 2011
Date of Patent:
July 16, 2019
Assignee:
Abbott Molecular Inc.
Inventors:
Irina A. Sokolova, Steven A. Seelig, Larry E. Morrison, Walter King, Alicia Algeciras-Schimnich